Artemether-lumefantrine 3 days — Competitive Intelligence Brief

Artemether-lumefantrine 3 days (Artemether-lumefantrine 3 days) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artemisinin-based combination therapy (ACT). Area: Infectious Disease / Parasitology.

phase 3 Artemisinin-based combination therapy (ACT) Plasmodium falciparum parasites; artemether targets multiple parasite proteins; lumefantrine inhibits heme polymerization Infectious Disease / Parasitology Small molecule

Target snapshot

Artemether-lumefantrine 3 days (Artemether-lumefantrine 3 days) — University of Oxford. Artemether-lumefantrine is a fixed-dose combination antimalarial that kills malaria parasites through multiple mechanisms: artemether rapidly reduces parasite biomass while lumefantrine eliminates remaining parasites and prevents recrudescence.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artemether-lumefantrine 3 days TARGET	Artemether-lumefantrine 3 days	University of Oxford	phase 3	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum parasites; artemether targets multiple parasite proteins; lumefantrine inhibits heme polymerization
Arterakine (DHA/piperaquine)	Arterakine (DHA/piperaquine)	Oxford University Clinical Research Unit, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum and other malaria parasites (multiple targets including heme polymerization and oxidative stress pathways)
Artesunate-Amodiaquine (ASAQ)	Artesunate-Amodiaquine (ASAQ)	University of Oxford	marketed	Artemisinin-based combination therapy (ACT)	Parasite protein synthesis and hemozoin formation
DHA - PPQ group	DHA - PPQ group	National Institute of Malariology, Parasitology and Entomology, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium spp.) — multiple targets including heme detoxification pathway and protein synthesis
Artemether+Lumefantrine (AL)	Artemether+Lumefantrine (AL)	Centers for Disease Control and Prevention	marketed	Artemisinin-based combination therapy (ACT)	Parasite heme metabolism; hemozoin formation
Dihydroartemisinine-piperaquine	Dihydroartemisinine-piperaquine	Ministry of Public Health, Democratic Republic of the Congo	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium species); multiple parasite targets including heme detoxification pathway
Arterakin (DHA-PPQ)	Arterakin (DHA-PPQ)	National Institute of Malariology, Parasitology and Entomology, Vietnam	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum heme; parasite food vacuole

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artemisinin-based combination therapy (ACT) class)

1. University of Oxford · 6 drugs in this class
2. Centro de Investigacao em Saude de Manhica · 2 drugs in this class
3. National Institute of Malariology, Parasitology and Entomology, Vietnam · 2 drugs in this class
4. Centers for Disease Control and Prevention · 1 drug in this class
5. Oxford University Clinical Research Unit, Vietnam · 1 drug in this class
6. University Clinical Research Center, Mali · 1 drug in this class
7. Ministry of Public Health, Democratic Republic of the Congo · 1 drug in this class
8. London School of Hygiene and Tropical Medicine · 1 drug in this class
9. Malaria Consortium, Uganda · 1 drug in this class